Novo Nordisk expands insulin production
expansion of its insulin manufacturing facility in Clayton, US. The
company has awarded the contract to BE&K Engineering and Suitt
Construction for the 19,000-square-foot expansion, due to start in
June this year.
Danish Novo Nordisk plans to break ground on a €10 million expansion of its insulin manufacturing facility in Clayton, US. The company has awarded the contract to BE&K Engineering and Suitt Construction for the 19,000-square-foot expansion, due to start in June this year.
"The expansion of our highly automated and stringently controlled facility further underscores our level of commitment to serving the insulin needs of people throughout the world who are living with diabetes," said John R. Pratt, general manager, Novo Nordisk Pharmaceutical Industries.
The Clayton manufacturing facility handles the formulation, filling and packaging of Novo Nordisk's genetically engineered insulin preparations.
According to the company, the new two-story addition, due for completion in early 2004, will expand the facility's quality inspection and cold storage capabilities and quality control laboratories. It also will provide additional administrative and employee areas.
Novo Nordisk claims that this latest move will help it to meet the ever-increasing demand coming from the US diabetes market.
